Target intelligence / Profile preview

Copper transporter protein 1 (CTR1)

Target
CTR1
Molecular classification
Transporter, Metal ion transporter; Copper transporter, SLC31 (CTR) family of copper transporters, Ion channel-like protein with transmembrane domains
01

Overview

Copper transporter protein 1 (CTR1), encoded by the SLC31A1 gene, is a high-affinity copper transporter that mediates copper uptake across cell membranes and plays a critical role in copper homeostasis across eukaryotes ranging from yeast to humans. CTR1 functions as a trimeric complex with three transmembrane domains and contains conserved methionine-rich metal-binding motifs that recognize and transport copper(I) ions through a mechanism involving sequential copper exchange reactions between defined binding sites. The protein is ubiquitously expressed with highest levels in the liver and is absolutely essential for normal mammalian embryonic development and proper functioning of copper-dependent enzymes including cytochrome c oxidase and superoxide dismutase. Beyond its physiological role in copper acquisition, CTR1 is a significant determinant of platinum-based chemotherapy efficacy, as cisplatin and related antitumor drugs exploit the copper transport machinery by binding to CTR1 and being carried intracellularly for their cytotoxic effects. Therapeutic targeting of CTR1 faces substantial challenges due to its essential role in development and the ubiquitous requirement for copper-dependent enzymes, though modulating CTR1 activity or expression may offer strategies to enhance chemotherapy sensitivity or address certain copper metabolism disorders.

Other names
High affinity copper uptake protein 1SLC31A1 gene producthCTR1 (human CTR1)COPT1 (in plant nomenclature)
02

Mechanism of action

CTR1 operates as a high-affinity copper transporter with energy-independent, potassium-dependent transport. It functions as a trimeric complex with a membrane-spanning pore created by symmetry-related transmembrane segments. The protein contains conserved methionine-rich (MPM and MxxxM) motifs in the N-terminus and transmembrane domain 2 that bind copper(I) ions. Copper transport occurs through a chain of copper exchange reactions between defined Cu(I)-binding sites with conformational switching. Cisplatin binds to extracellular domains and is carried intracellularly via CTR1 internalization. C-terminal cysteine-rich motifs bind copper and are essential for rapid inactivation in response to excess copper.

03

Biological functions

High-affinity copper uptake across cell membranes under low copper conditionsCopper acquisition and homeostasis in eukaryotesMediates copper translocation across cellular membranes into the cytoplasmSupplies copper to copper chaperones (ATOX1 and CCS) for incorporation into cuproproteinsEssential for embryonic development and mammalian copper homeostasis
04

Disease associations

Copper deficiency disorders: CTR1 knockout results in profound growth and developmental defects; heterozygous mice exhibit tissue-specific defects in copper accumulation and reduced activities of copper-dependent enzymesWilson disease association: While ATP7B is the primary transporter implicated in Wilson disease, CTR1 dysfunction could contribute to copper metabolism disordersNeurodegenerative disease potential: CTR1 expression is lowest in the brain and skeletal muscle, suggesting potential relevance to neurological conditions requiring copper-dependent enzymesCancer progression: Cisplatin uptake via CTR1 affects chemotherapy efficacy
05

Safety considerations

Essential for Embryonic Development: CTR1 is required for normal mammalian development; complete loss is embryonic lethal in mice, indicating significant safety constraints for systemic CTR1 inhibitionUbiquitous Expression: CTR1 is expressed ubiquitously with highest expression in the liver, creating potential for off-target effectsPleiotropic Effects: Disrupting CTR1 affects multiple copper-dependent enzymes and metabolic pathways, limiting therapeutic targeting approachesCisplatin Resistance: Altered CTR1 expression is associated with acquired resistance to platinum-based chemotherapyCopper Homeostasis Balance: Modulating CTR1 activity risks disrupting carefully regulated copper homeostasis
06

Interacting drugs

Cisplatin

1 more in the full profile.

07

Biomarkers

Patient Selection: CTR1 expression levels in tumor tissue may predict cisplatin sensitivity and chemotherapy responseCopper Status: CTR1 activity correlates with systemic copper bioavailability and copper-dependent enzyme activityEfficacy Monitoring: Copper accumulation in cells and tissues reflects CTR1 transporter function

Beyond the preview

Go deeper on Copper transporter protein 1 (CTR1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Copper transporter protein 1 (CTR1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call